At ASCO, AstraZeneca reports strong data for breast cancer drug – STAT
At ASCO, AstraZeneca reports strong data for breast cancer drug STATTrastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial…